{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:52:40Z","timestamp":1781830360978,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"This work was supported by Basic Science Research of the National Research Foundation of Korea (NRF) and funded by the Ministry of Science, ICT, and Future Planning Program","award":["2018R1DA1B07049449"],"award-info":[{"award-number":["2018R1DA1B07049449"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-50157-2","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:06:27Z","timestamp":1777043187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["miR-16-5p mediates E2-induced cell proliferation and EMT in benign prostate hyperplasia"],"prefix":"10.1038","volume":"16","author":[{"given":"Jung-Eun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leeseon","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinzhu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunseo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-Jeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"50157_CR1","first-page":"289","volume":"43","author":"KB Egan","year":"2016","unstructured":"Egan, K. B. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urologic Clin. 43, 289\u2013297 (2016).","journal-title":"Urologic Clin."},{"key":"50157_CR2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.21032\/jhis.2018.43.3.208","volume":"43","author":"HS Kim","year":"2018","unstructured":"Kim, H. S. et al. The prevalence of benign prostate hyperplasia in Korea: using national health insurance service data. J. Health Inf. Stat. 43, 208\u2013216 (2018).","journal-title":"J. Health Inf. Stat."},{"key":"50157_CR3","first-page":"443","volume":"36","author":"GB Auffenberg","year":"2009","unstructured":"Auffenberg, G. B., Helfand, B. T. & McVary, K. T. Established medical therapy for benign prostatic hyperplasia. Urologic Clin. 36, 443\u2013459 (2009).","journal-title":"Urologic Clin."},{"key":"50157_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1023\/A:1013004602682","volume":"10","author":"AS Salinas-S\u00e1nchez","year":"2001","unstructured":"Salinas-S\u00e1nchez, A. S. et al. Quality of life of patients on the waiting list for benign prostatic hyperplasia surgery. Qual. Life Res. 10, 543\u2013553 (2001).","journal-title":"Qual. Life Res."},{"key":"50157_CR5","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.4040\/jkan.2005.35.8.1508","volume":"35","author":"EH Lee","year":"2005","unstructured":"Lee, E. H., Chun, K. H. & Lee, Y. Benign prostatic hyperplasia in community-dwelling elderly in Korea. J. Korean Acad. Nurs. 35, 1508\u20131513 (2005).","journal-title":"J. Korean Acad. Nurs."},{"key":"50157_CR6","first-page":"547","volume":"46","author":"SJ HONG","year":"2005","unstructured":"HONG, S. J. Benign prostatic hyperplasia: Multiple factors for prostate tissue change with aging. Korean J. Urology 46, 547\u2013554 (2005).","journal-title":"Korean J. Urology"},{"key":"50157_CR7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41419-022-04979-3","volume":"13","author":"Y Yang","year":"2022","unstructured":"Yang, Y. et al. Estrogen and G protein-coupled estrogen receptor accelerate the progression of benign prostatic hyperplasia by inducing prostatic fibrosis. Cell Death Dis. 13, 533 (2022).","journal-title":"Cell Death Dis."},{"key":"50157_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13098-015-0089-1","volume":"7","author":"A Ry\u0142","year":"2015","unstructured":"Ry\u0142, A. et al. Metabolic syndrome and benign prostatic hyperplasia: association or coincidence? Diabetol. Metab. Syndr. 7, 1\u20137 (2015).","journal-title":"Diabetol. Metab. Syndr."},{"key":"50157_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jmhg.2005.03.009","volume":"2","author":"S Rohrmann","year":"2005","unstructured":"Rohrmann, S., Platz, E. A. & Giovannucci, E. Lifestyle and benign prostatic hyperplasia in older men: what do we know? J. Men\u2019s Health Gend. 2, 230\u2013235 (2005).","journal-title":"J. Men\u2019s Health Gend."},{"key":"50157_CR10","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.diff.2011.04.006","volume":"82","author":"TM Nicholson","year":"2011","unstructured":"Nicholson, T. M. & Ricke, W. A. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation 82, 184\u2013199 (2011).","journal-title":"Differentiation"},{"key":"50157_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.exger.2004.12.008","volume":"40","author":"G Untergasser","year":"2005","unstructured":"Untergasser, G., Madersbacher, S. & Berger, P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp. Gerontol. 40, 121\u2013128 (2005).","journal-title":"Exp. Gerontol."},{"key":"50157_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1210\/jcem-57-1-71","volume":"57","author":"JM Davidson","year":"1983","unstructured":"Davidson, J. M. et al. Hormonal changes and sexual function in aging men. J. Clin. Endocrinol. Metabolism. 57, 71\u201377 (1983).","journal-title":"J. Clin. Endocrinol. Metabolism"},{"key":"50157_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1080\/tam.5.2.98.102","volume":"5","author":"A Vermeulen","year":"2002","unstructured":"Vermeulen, A., Kaufman, J. & Goemaere, S. Van Pottelberg, I. Estradiol in elderly men. aging male. 5, 98\u2013102 (2002).","journal-title":"aging male"},{"key":"50157_CR14","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1152\/physrev.00018.2016","volume":"97","author":"PS Cooke","year":"2017","unstructured":"Cooke, P. S., Nanjappa, M. K., Ko, C., Prins, G. S. & Hess, R. A. Estrogens in male physiology. Physiol. Rev. 97, 995\u20131043 (2017).","journal-title":"Physiol. Rev."},{"key":"50157_CR15","doi-asserted-by":"publisher","first-page":"107499","DOI":"10.1016\/j.nlm.2021.107499","volume":"184","author":"LO de Souza","year":"2021","unstructured":"de Souza, L. O. et al. The G protein-coupled estrogen receptor (GPER) regulates recognition and aversively\u2013motivated memory in male rats. Neurobiol. Learn. Mem. 184, 107499 (2021).","journal-title":"Neurobiol. Learn. Mem."},{"key":"50157_CR16","first-page":"3853","volume":"17","author":"N Zhang","year":"2018","unstructured":"Zhang, N. et al. MicroRNA expression profiles in benign prostatic hyperplasia. Mol. Med. Rep. 17, 3853\u20133858 (2018).","journal-title":"Mol. Med. Rep."},{"key":"50157_CR17","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.euf.2018.01.008","volume":"5","author":"F Greco","year":"2019","unstructured":"Greco, F. et al. The potential role of microRNAs as biomarkers in benign prostatic hyperplasia: a systematic review and meta-analysis. Eur. Urol. Focus. 5, 497\u2013507 (2019).","journal-title":"Eur. Urol. Focus"},{"key":"50157_CR18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12894-022-01121-5","volume":"22","author":"Z Liu","year":"2022","unstructured":"Liu, Z. et al. Upregulation of mir-1199-5p is associated with reduced type 2 5-\u03b1 reductase expression in benign prostatic hyperplasia. BMC Urol. 22, 172 (2022).","journal-title":"BMC Urol."},{"key":"50157_CR19","doi-asserted-by":"publisher","first-page":"FSO304","DOI":"10.4155\/fsoa-2018-0012","volume":"4","author":"T Tanaka","year":"2018","unstructured":"Tanaka, T. et al. Urine miR-21-5p as a potential biomarker for predicting effectiveness of tadalafil in benign prostatic hyperplasia. Future Sci. OA. 4, FSO304 (2018).","journal-title":"Future Sci. OA"},{"key":"50157_CR20","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.3390\/pharmaceutics15071885","volume":"15","author":"JE Kim","year":"2023","unstructured":"Kim, J. E., Han, H., Xu, Y., Lee, M. H. & Lee, H. J. Efficacy of FRO on acne vulgaris pathogenesis. Pharmaceutics 15, 1885 (2023).","journal-title":"Pharmaceutics"},{"key":"50157_CR21","first-page":"295","volume":"12","author":"Y Chen","year":"2019","unstructured":"Chen, Y. et al. Hypoxia-inducible factor 1\u03b1 (HIF-1\u03b1) mediates the epithelial-mesenchymal transition in benign prostatic hyperplasia. Int. J. Clin. Exp. Pathol. 12, 295 (2019).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"50157_CR22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/CU9.0000000000000233","volume":"18","author":"T Zhang","year":"2024","unstructured":"Zhang, T. et al. Hypoxia activates the hypoxia-inducible factor-1\u03b1\/vascular endothelial growth factor pathway in a prostatic stromal cell line: A mechanism for the pathogenesis of benign prostatic hyperplasia. Curr. Urol. 18, 185\u2013193 (2024).","journal-title":"Curr. Urol."},{"key":"50157_CR23","doi-asserted-by":"publisher","first-page":"12053","DOI":"10.18632\/oncotarget.7641","volume":"7","author":"F Wu","year":"2016","unstructured":"Wu, F. et al. Elevated expression of HIF-l\u03b1 in actively growing prostate tissues is associated with clinical features of benign prostatic hyperplasia. Oncotarget 7, 12053 (2016).","journal-title":"Oncotarget"},{"key":"50157_CR24","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/iju.14265","volume":"27","author":"J Hata","year":"2020","unstructured":"Hata, J. et al. Morphological change and characteristics of myofibroblasts during the growth process of benign prostatic hyperplasia. Int. J. Urol. 27, 676\u2013683 (2020).","journal-title":"Int. J. Urol."},{"key":"50157_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/jcm7040068","volume":"7","author":"K Ishii","year":"2018","unstructured":"Ishii, K., Takahashi, S., Sugimura, Y. & Watanabe, M. Role of stromal paracrine signals in proliferative diseases of the aging human prostate. J. Clin. Med. 7, 68 (2018).","journal-title":"J. Clin. Med."},{"key":"50157_CR26","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.4161\/cc.10.8.15326","volume":"10","author":"C Culver","year":"2011","unstructured":"Culver, C., Melvin, A., Mudie, S. & Rocha, S. HIF-1\u03b1 depletion results in SP1-mediated cell cycle disruption and alters the cellular response to chemotherapeutic drugs. Cell. cycle. 10, 1249\u20131260 (2011).","journal-title":"Cell. cycle"},{"key":"50157_CR27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.bbamcr.2007.11.017","volume":"1783","author":"YS Cho","year":"2008","unstructured":"Cho, Y. S. et al. HIF-1\u03b1 controls keratinocyte proliferation by up-regulating p21 (WAF1\/Cip1). Biochim. et Biophys. Acta (BBA)-Molecular Cell. Res. 1783, 323\u2013333 (2008).","journal-title":"Biochim. et Biophys. Acta (BBA)-Molecular Cell. Res."},{"key":"50157_CR28","doi-asserted-by":"publisher","first-page":"119683","DOI":"10.1016\/j.bbamcr.2024.119683","volume":"1871","author":"J Dreute","year":"2024","unstructured":"Dreute, J., Pfisterer, M. & Schmitz, M. L. A reductionist perspective on HIF-1\u03b1\u2019s role in cell proliferation under non-hypoxic conditions. Biochim. et Biophys. Acta (BBA)-Molecular Cell. Res. 1871, 119683 (2024).","journal-title":"Biochim. et Biophys. Acta (BBA)-Molecular Cell. Res."},{"key":"50157_CR29","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/j.1749-6632.2009.04360.x","volume":"1155","author":"SJ Ellem","year":"2009","unstructured":"Ellem, S. J. & Risbridger, G. P. The dual, opposing roles of estrogen in the prostate. Ann. N. Y. Acad. Sci. 1155, 174\u2013186 (2009).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"50157_CR30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/pros.2990170308","volume":"17","author":"H Guess","year":"1990","unstructured":"Guess, H., Arrighi, H., Metter, E. & Fozard, J. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate 17, 241\u2013246 (1990).","journal-title":"Prostate"},{"key":"50157_CR31","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0094-0143(21)00961-7","volume":"17","author":"J McNeal","year":"1990","unstructured":"McNeal, J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urologic. Clin. North. Am. 17, 477\u2013486 (1990).","journal-title":"Urologic. Clin. North. Am."},{"key":"50157_CR32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000052410","volume":"39","author":"GB \u00d8verland","year":"2001","unstructured":"\u00d8verland, G. B. et al. Lower urinary tract symptoms, prostate volume and uroflow in norwegian community men. Eur. Urol. 39, 36\u201341 (2001).","journal-title":"Eur. Urol."},{"key":"50157_CR33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1677\/JME-07-0053","volume":"39","author":"GP Risbridger","year":"2007","unstructured":"Risbridger, G. P., Ellem, S. J. & McPherson, S. J. Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling. J. Mol. Endocrinol. 39, 183\u2013188 (2007).","journal-title":"J. Mol. Endocrinol."},{"key":"50157_CR34","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000473774","volume":"29","author":"E Bierhoff","year":"1996","unstructured":"Bierhoff, E. et al. Stromal nodules in benign prostatic hyperplasia. Eur. Urol. 29, 345\u2013354 (1996).","journal-title":"Eur. Urol."},{"key":"50157_CR35","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1159\/000480835","volume":"32","author":"Y Xue","year":"1997","unstructured":"Xue, Y. et al. Changes in keratin expression during the development of benign prostatic hyperplasia. Eur. Urol. 32, 332\u2013338 (1997).","journal-title":"Eur. Urol."},{"key":"50157_CR36","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/pros.23404","volume":"77","author":"X Shi","year":"2017","unstructured":"Shi, X. et al. Estradiol promotes epithelial-to\u2010mesenchymal transition in human benign prostatic epithelial cells. Prostate 77, 1424\u20131437 (2017).","journal-title":"Prostate"},{"key":"50157_CR37","first-page":"2775","volume":"61","author":"H Xu","year":"2017","unstructured":"Xu, H. et al. DNMT1 regulates IL-6-and TGF-\u03b21-induced epithelial mesenchymal transition in prostate epithelial cells. Eur. J. Histochemistry: EJH. 61, 2775 (2017).","journal-title":"Eur. J. Histochemistry: EJH"},{"key":"50157_CR38","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.2217\/fon.15.253","volume":"11","author":"SA Broster","year":"2015","unstructured":"Broster, S. A. & Kyprianou, N. Epithelial\u2013mesenchymal transition in prostatic disease. Future Oncol. 11, 3197\u20133206 (2015).","journal-title":"Future Oncol."},{"key":"50157_CR39","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1073\/pnas.0812666106","volume":"106","author":"P Alonso-Magdalena","year":"2009","unstructured":"Alonso-Magdalena, P. et al. A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. Proc. Natl. Acad. Sci. 106, 2859\u20132863 (2009).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"50157_CR40","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.juro.2014.08.093","volume":"193","author":"TM Nicholson","year":"2015","unstructured":"Nicholson, T. M. et al. Estrogen receptor-\u03b1 is a key mediator and therapeutic target for bladder complications of benign prostatic hyperplasia. J. Urol. 193, 722\u2013729 (2015).","journal-title":"J. Urol."},{"issue":"3","key":"50157_CR41","doi-asserted-by":"publisher","first-page":"109125","DOI":"10.1016\/j.isci.2024.109125","volume":"27","author":"Z Liu","year":"2024","unstructured":"Liu, Z. et al. YAP-mediated GPER signaling impedes proliferation and survival of prostate epithelium in benign prostatic hyperplasia. Iscience 27(3), (2024).","journal-title":"Iscience"},{"key":"50157_CR42","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/ncb1691","volume":"10","author":"MH Yang","year":"2008","unstructured":"Yang, M. H. et al. Direct regulation of TWIST by HIF-1\u03b1 promotes metastasis. Nat. Cell Biol. 10, 295\u2013305 (2008).","journal-title":"Nat. Cell Biol."},{"key":"50157_CR43","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1210\/en.2006-1394","volume":"148","author":"AA Kazi","year":"2007","unstructured":"Kazi, A. A. & Koos, R. D. Estrogen-induced activation of hypoxia-inducible factor-1\u03b1, vascular endothelial growth factor expression, and edema in the uterus are mediated by the phosphatidylinositol 3-kinase\/Akt pathway. Endocrinology 148, 2363\u20132374 (2007).","journal-title":"Endocrinology"},{"key":"50157_CR44","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.biopha.2018.05.041","volume":"104","author":"W Jin","year":"2018","unstructured":"Jin, W. et al. miR-15a\/miR-16 cluster inhibits invasion of prostate cancer cells by suppressing TGF-\u03b2 signaling pathway. Biomed. Pharmacother. 104, 637\u2013644 (2018).","journal-title":"Biomed. Pharmacother."},{"key":"50157_CR45","first-page":"247","volume":"39","author":"H Wang","year":"2018","unstructured":"Wang, H., Zhang, Y., Wu, Q., Wang, Y. B. & Wang, W. miR-16 mimics inhibit TGF-\u03b21-induced epithelial-to-mesenchymal transition via activation of autophagy in non-small cell lung carcinoma cells. Oncol. Rep. 39, 247\u2013254 (2018).","journal-title":"Oncol. Rep."},{"key":"50157_CR46","first-page":"5950","volume":"17","author":"Z Li","year":"2018","unstructured":"Li, Z. et al. miR-16 inhibits hyperoxia-induced cell apoptosis in human alveolar epithelial cells. Mol. Med. Rep. 17, 5950\u20135957 (2018).","journal-title":"Mol. Med. Rep."},{"key":"50157_CR47","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.bbrc.2021.05.046","volume":"561","author":"Y Bo","year":"2021","unstructured":"Bo, Y., Liu, B., Yang, L., Zhang, L. & Yan, Y. Exosomes derived from miR-16-5p-overexpressing keratinocytes attenuates bleomycin-induced skin fibrosis. Biochem. Biophys. Res. Commun. 561, 113\u2013119 (2021).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"50157_CR48","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50157-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50157-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50157-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:03:27Z","timestamp":1781827407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50157-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["50157"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-50157-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19057"}}